Literature DB >> 6408492

The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions.

A M O'Carroll, C J Fowler, J P Phillips, I Tobbia, K F Tipton.   

Abstract

The deamination of dopamine has been studied in seven regions of human brain. Both A and B forms of the enzyme were found to be active towards this substrate. The ratio of activities of MAO-A: MAO-B was found to vary considerably from brain region to brain region, from about 1:1 for the cerebral and cerebellar cortex to about 1:2 for the pons and medulla oblongata. Enzyme titration studies and comparisons of the substrate specificities of MAO-A and MAO-B across the brain indicated that dopamine was metabolised by the same MAO active centres as other monoamines. In the cerebral cortex, the Km values of MAO-A and -B towards dopamine were found to be 210 and 230 microM, respectively, indicating that the relative contributions of these two forms towards the oxidation of this substrate will not be significantly affected by changes in its concentration.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6408492     DOI: 10.1007/BF00500765

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  30 in total

1.  Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine.

Authors:  A R Green; B D Mitchell; A F Tordoff; M B Youdim
Journal:  Br J Pharmacol       Date:  1977-07       Impact factor: 8.739

2.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

3.  A kinetic evaluation of monoamine oxidase activity in rat liver mitochondrial outer membranes.

Authors:  M D Houslay; K F Tipton
Journal:  Biochem J       Date:  1974-06       Impact factor: 3.857

4.  Some puzzling pharmacological effects of monoamine oxidase inhibitors.

Authors:  J Knoll; K Magyar
Journal:  Adv Biochem Psychopharmacol       Date:  1972

5.  Deamination of dopamine and its 3-O-methylated derivative by human brain monoamine oxidase.

Authors:  J A Roth; K Feor
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

6.  Substrate selectivity of type A and type B monoamine oxidase in rat brain.

Authors:  H Kinemuchi; Y Wakui; K Kamijo
Journal:  J Neurochem       Date:  1980-07       Impact factor: 5.372

7.  The nature of inhibition of cat brain mitochondrial monoamine oxidase by clorgyline.

Authors:  M B Youdim; B Holman
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

8.  Evidence for a single catalytic binding site on human brain type B monoamine oxidase.

Authors:  J A Roth
Journal:  J Neurochem       Date:  1976-11       Impact factor: 5.372

9.  Oxidation of beta-phenylethylamine by both types of monoamine oxidase: examination of enzymes in brain and liver mitochondria of eight species.

Authors:  O Suzuki; Y Katsumata; M Oya
Journal:  J Neurochem       Date:  1981-03       Impact factor: 5.372

10.  Dopamine oxidation and its inhibition by (-)-deprenyl in man.

Authors:  V Glover; J D Elsworth; M Sandler
Journal:  J Neural Transm Suppl       Date:  1980
View more
  47 in total

1.  Expression of monoamine oxidase B activity in astrocytes of senile plaques.

Authors:  S Nakamura; T Kawamata; I Akiguchi; M Kameyama; N Nakamura; H Kimura
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

2.  Increased binding of 3H-L-deprenyl in spinal cords from patients with amyotrophic lateral sclerosis as demonstrated by autoradiography.

Authors:  S M Aquilonius; S S Jossan; J G Ekblom; H Askmark; P G Gillberg
Journal:  J Neural Transm Gen Sect       Date:  1992

3.  Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.

Authors:  O Sader-Mazbar; Y Loboda; M J Rabey; J P M Finberg
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

4.  Interactions of the neurotoxin MPTP and its demethylated derivative (PTP) with monoamine oxidase-B.

Authors:  J P Sullivan; K F Tipton
Journal:  Neurochem Res       Date:  1992-08       Impact factor: 3.996

Review 5.  The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression.

Authors:  Eleni Pitsillou; Sarah M Bresnehan; Evan A Kagarakis; Stevano J Wijoyo; Julia Liang; Andrew Hung; Tom C Karagiannis
Journal:  Mol Biol Rep       Date:  2019-10-14       Impact factor: 2.316

Review 6.  Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

Authors:  John P M Finberg
Journal:  J Neural Transm (Vienna)       Date:  2018-11-01       Impact factor: 3.575

7.  Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat.

Authors:  P Celada; F Artigas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-06       Impact factor: 3.000

8.  Pharmacokinetics of Rasagiline in Healthy Adult Chinese Volunteers with Various Genotypes: A Single-Center, Open-Label, Multiple-Dose Study.

Authors:  Xia Chen; Qian Zhao; Ji Jiang; Jian Liu; Pei Hu
Journal:  Clin Drug Investig       Date:  2016-05       Impact factor: 2.859

9.  Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain.

Authors:  M K Lakshmana; B S Rao; N K Dhingra; R Ravikumar; S Sudha; B L Meti; T R Raju
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

10.  Homeostatic mechanisms in dopamine synthesis and release: a mathematical model.

Authors:  Janet A Best; H Frederik Nijhout; Michael C Reed
Journal:  Theor Biol Med Model       Date:  2009-09-10       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.